Eurofins Scientific (ERF) Q4 2024 earnings summary

Executive summary

• Achieved record annual revenues of €6,951m in FY 2024, up 6.7% year-over-year, surpassing pre-pandemic levels and COVID-19 peaks, with strong margin and cash flow growth, resuming historic growth trends.

• Adjusted EBITDA rose 14% to €1,552m, with margin improving 140bps to 22.3%; net profit increased 32% to €405m and EPS by 41%.

• Organic growth in the Core Business was 4.7%, with softness limited to less than 10% of Group revenues.

• Major investments in infrastructure, IT, and start-ups continue, but the group is nearing the end of a major investment cycle, with benefits expected to materialize by 2027.

• Share buybacks prioritized due to undervaluation, with €290m spent in 2024 and 70% of COVID-era shares repurchased.

Financial highlights

• Revenues grew 6.7% year-over-year to €6,951m; organic growth was 4.7%.

• Adjusted EBITDA margin rose by 140–180bps to 22.3%; net profit up 32% to €405m; EPS up 41% to €1.87.

• Free cash flow to the firm surged 69% to €801m, with a 56% cash conversion rate.

• Net working capital improved to 3.8% of revenues; net operating capex declined to 5.2% of revenues.

• Financial leverage at 1.9x, improved despite share buybacks; net debt at €2,996m.

Outlook and guidance

• Long-term organic growth target reaffirmed at 6.5% per annum, with 2025 guidance set at mid-single-digit growth and €250m in acquisition revenues.

• Margin target of 24% by 2027 remains, with mature scope already close to this level.

• Free cash flow conversion target set at 50%+, with flexibility depending on CapEx and market conditions.

• Financial leverage to remain within 1.5–2.5x, aiming for the lower end by 2027.

• Progression on margin and cash flow expected to be stronger in H2 2025.